This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Beat the Market the Zacks Way: ORIX, Starbucks, Alphabet in Focus
by Santanu Roy
IX, SBUX and GOOGL rallied after Zacks upgrades and portfolio additions, while major indexes stayed volatile amid Fed and inflation concerns.
PAYXPositive Net Change PWRNegative Net Change NVOPositive Net Change SBUXNegative Net Change FDSPositive Net Change MPWRNegative Net Change IXPositive Net Change GOOGLNegative Net Change NOBLNegative Net Change ASMIYPositive Net Change LEGHNegative Net Change INDVNegative Net Change
business-services communications computers construction finance internet medical pharmaceuticals restaurants semiconductor
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
by Kinjel Shah
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
LLYNegative Net Change JNJNegative Net Change NVOPositive Net Change BAYRYNegative Net Change
pharmaceuticals
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
by Zacks Equity Research
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.
PFEPositive Net Change MRKNegative Net Change ALPMYPositive Net Change
biotechs medical pharmaceuticals
AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors
by Zacks Equity Research
AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.
AZNPositive Net Change RHHBYPositive Net Change IMCRNegative Net Change JSPRNegative Net Change
biotechs pharmaceuticals
GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
by Zacks Equity Research
Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.
MRKNegative Net Change GILDNegative Net Change LQDANegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Backs EU Approval of Novo Nordisk's Wegovy Pill for Obesity
by Zacks Equity Research
NVO's Wegovy pill gets CHMP backing, moving it closer to becoming the first oral GLP-1 treatment approved in the EU for weight management.
NVOPositive Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
by Zacks Equity Research
Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.
LQDANegative Net Change BDTXNegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
by Zacks Equity Research
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
SNYNegative Net Change BIIBNegative Net Change DNLIPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?
by Ekta Bagri
ADMA cuts 2026 guidance after weak Bivigam sales and IG market pressure weigh on revenues amid rising competition and order volatility.
GRFSNegative Net Change ADMAPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?
by Kanishka Das
Merck's Gardasil sales plunge as weak China demand, inventory issues and softer Japan trends cloud the vaccine's overall growth outlook in 2026.
SNYNegative Net Change AZNPositive Net Change MRKNegative Net Change
pharmaceuticals